Favorable outcomes of COVID-19 in vaccinated hematopoietic stem cell transplant recipients: A single-center experience.
Jing Yuan TanLiang En WeeYi Hern TanEdwin Philip ConceicaoFrancesca Wei Inng LimYunxin ChenHein ThanJeffrey Kim Siang QuekChandramouli NagarajanYeow Tee GohWilliam Ying Khee HwangGhee Chee PhuaShimin Jasmine ChungThuan Tong TanYeh Ching LinnAloysius Yew Leng HoBan Hock TanPublished in: Transplant infectious disease : an official journal of the Transplantation Society (2023)
We observed favorable outcomes with COVID-19 infection in a cohort of vaccinated HSCT patients. The SARS-CoV-2 omicron variant was associated with both less severe illness and decreased odds of mortality. As COVID-19 moves toward endemicity, early access to treatment and encouraging vaccination uptake is crucial in mitigating the challenge of COVID-19 management among HSCT recipients. Surveillance and assessment of clinical outcomes with new SARS-CoV-2 variants also remains important in this immunocompromised population.
Keyphrases
- sars cov
- hematopoietic stem cell
- respiratory syndrome coronavirus
- coronavirus disease
- end stage renal disease
- newly diagnosed
- ejection fraction
- public health
- peritoneal dialysis
- prognostic factors
- type diabetes
- risk factors
- patient reported outcomes
- copy number
- cardiovascular disease
- dna methylation
- skeletal muscle
- insulin resistance
- mechanical ventilation